Quimark

What Quimark does

Quimark is an Italian B2B distributor specializing in CE-IVD genomic diagnostic kits for oncology, headquartered in Milan and operating across Italy's hospital, pathology laboratory, and oncology department channels. The company's portfolio comprises eight CE-IVD certified tests covering the major oncology decision points: breast cancer prognosis and chemotherapy benefit (EndoPredict, DiviTum TKa), prostate cancer risk stratification (Prolaris), ovarian cancer HRD testing for PARP inhibitor selection (MyChoice CDx Plus), bladder cancer detection and recurrence surveillance (Canhelp-UCa), tumor-of-origin identification for carcinomas of unknown primary (Canhelp-Origin), hereditary cancer risk assessment via a 48-gene germline panel (MyRisk Plus), and microbiota-based prediction of immunotherapy response (BiomeOne). Underlying technologies span RT-qPCR gene expression analysis from FFPE tissue and urine, ELISA-based serum proliferation assays, and microbial DNA analysis from fecal samples, with AI-assisted software used in Canhelp-Origin and Canhelp-UCa for result interpretation. Quimark does not manufacture its products; the portfolio is sourced through exclusive or primary Italian distribution agreements with Myriad Genetics (USA), Canhelp Genomics (China), Biovica (Sweden), and Biome-Dx (Austria), with two tests (MyChoice CDx Plus and MyRisk Plus) physically performed at Myriad's US laboratories on Italian patient samples.

Quimark operates a direct B2B enterprise sales model, selling CE-IVD kits to institutional buyers under quote-based pricing with no public list prices. The company markets through clinical evidence-based content, conference participation, and a LinkedIn professional channel. In March 2025, Quimark was acquired by French-headquartered Eurobio Scientific, and effective October 7, 2025, Quimark Srl merged by incorporation into DID S.p.A., another Eurobio group entity. The merged Italian operation now operates under the Eurobio-DID brand with revenue pooled into the broader Eurobio Scientific group (€168M 2025 revenue, up 9% year-over-year, with 42% of group sales generated internationally outside France). Standalone Quimark revenue, employee count details, and ownership history prior to the acquisition are not disclosed.

Name

Quimark

Legal name

Quimark Srl

Website

https://quimark.com

Company type

Private

Operating status

Acquired

Headcount range

1–10 employees

Short description

Quimark is an Italian B2B distributor of CE-IVD genomic diagnostic kits for oncology, supplying hospitals, pathology laboratories, and oncology departments in Italy with a portfolio of eight clinically validated tests spanning breast, prostate, ovarian, bladder, hereditary, and immunotherapy-response applications.

Ownership category

akta.pro rank

Product category

Oncology Diagnostics Distribution

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Oncology diagnostic distribution
• Genomic testing products
• CE-IVD medical devices
• Molecular diagnostics supply
• Cancer diagnostic kits

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Distribution of CE-IVD Diagnostic Kits: Quimark distributes genomic diagnostic kits (EndoPredict, Prolaris, Canhelp-Origin, Canhelp-UCa, DiviTum TKa, BiomeOne) to hospitals and molecular pathology laboratories in Italy. Revenue is generated through product sales of diagnostic kits to healthcare institutions. As of 2025, Quimark merged into DID S.p.A. (Eurobio Scientific group), integrating with the group's proprietary product portfolio which represents 35% of Eurobio Scientific's total revenue.
2. Laboratory Testing Services (MyChoice CDx Plus, MyRisk Plus): Certain tests (MyChoice CDx Plus and MyRisk Plus) are performed in Myriad Genetics USA laboratories on patient samples sent from Italy. Quimark acts as the local distributor/channel partner, facilitating sample logistics and reporting results to Italian physicians. Revenue flows through distribution fees and kit sales.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Quimark is an Italian B2B distributor of CE-IVD genomic diagnostic kits for oncology, serving hospitals, molecular pathology laboratories, and oncology departments across Italy. The company sells a portfolio of eight CE-IVD certified molecular diagnostic tests covering breast, prostate, ovarian, bladder, hereditary, and unknown-origin cancers, and facilitates laboratory testing services with international partner laboratories (Myriad Genetics in USA, Biome-Dx in Austria) for select products.

Product overview

Quimark (as of October 7, 2025, merged with DID S.p.A. and integrated into the Eurobio Scientific group) is an Italian distributor of oncological genomic diagnostic products. The portfolio spans eight distinct CE-IVD test products addressing multiple cancer types: breast cancer (EndoPredict for ER+/HER2- early-stage prognosis and chemotherapy guidance; DiviTum TKa for metastatic HR+ monitoring), prostate cancer (Prolaris for aggressiveness stratification), ovarian cancer (MyChoice CDx Plus for HRD/PARP inhibitor selection), bladder cancer (Canhelp-UCa for early detection and recurrence monitoring), tumors of unknown primary (Canhelp-Origin for tissue-of-origin identification), hereditary cancer risk (MyRisk Plus for 48-gene germline screening), and immunotherapy response prediction (BiomeOne for microbiota-based ICI outcome forecasting). The products differ in sample type (FFPE tissue, urine, blood, fecal), technology (RT-QPCR, ELISA, microbial DNA analysis), and use setting (in-house laboratory vs. partner laboratories in the USA and Austria).

Differentiator

Problem solved

Functional benefit

Products and services

• EndoPredict Second-generation CE-IVD genomic prognostic-predictive test for early-stage hormone receptor-positive (ER+/HER2-) breast cancer. Quantifies expression of 12 genes via RT-QPCR from FFPE tumor tissue and integrates molecular data with clinical parameters (tumor size, lymph node status) to generate the EPclin score, which predicts 10-year and up to 15-year recurrence risk and chemotherapy benefit. Level of Evidence 1A per ESMO guidelines. For molecular pathology laboratories and hospital oncology departments in Italy.
• Prolaris CE-IVD prognostic genomic test for prostate cancer that measures expression of genes involved in tumor cell proliferation and combines them with clinical parameters (PSA, Gleason score) to generate a Cell Cycle Progression (CCP) risk score. Helps stratify patient risk for active surveillance versus definitive/single/multimodal treatment decisions. Validated for all NCCN risk groups and trusted by over 5 million patients globally. For urologists, prostate cancer specialists, and pathology laboratories in Italy.
• Canhelp-Origin CE-IVD molecular diagnostic test that uses quantitative RT-PCR on FFPE tumor tissue to identify the primary site of metastatic tumors (Carcinoma of Unknown Primary, CUP). Evaluates expression of 90 genes across 21 tumor types covering more than 95% of solid tumors by global incidence, with over 90% overall accuracy. Results are analyzed by Canhelp-Origin Software (CE-IVD) which generates similarity scores for each tumor type. Validated on over 3,000 cancer patients with 18+ published scientific articles. For pathology laboratories and hospital oncology departments treating CUP cases in Italy.
• Canhelp-UCa CE-IVD diagnostic test for urothelial (bladder) cancer detection and recurrence monitoring using urine samples. Evaluates expression of 8 genes (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2, SWINGN) via RT-PCR. AI-powered software generates a probability score (≥50 positive, <50 negative). Achieves 93.4% accuracy, 92.3% sensitivity, and 94.1% specificity across all tumor stages as a non-invasive alternative to cystoscopy. For urology departments, oncology centers, and pathology laboratories in Italy.
• DiviTum TKa CE-IVD quantitative test measuring thymidine kinase 1 (TK1) activity in blood serum via multi-step endpoint ELISA technology. Provides a DiviTum activity score reflecting tumor proliferative status, useful for early prognosis and treatment efficacy assessment in HR+ metastatic breast cancer. A negative test result indicates 97% probability of no tumor progression within 30 days. Serves as a complementary tool to imaging between radiological examinations. For medical oncologists and laboratory medicine departments in Italy.
• MyChoice CDx Plus CE-IVD companion diagnostic test for ovarian cancer that determines Homologous Recombination Deficiency (HRD) status to guide PARP inhibitor therapy. Combines BRCA1/2 mutation detection (sequence variants and large rearrangements) with Genomic Instability Score (GIS) assessment via LOH, TAI, and LST across 27,000 SNPs. The only HRD test with FDA approval, CE certification, Level of Evidence 1A, and prospective Phase III validation (PAOLA-1, PRIMA, VELIA trials). HRD is present in approximately 48% of ovarian tumors. For gynecologic oncologists and pathology laboratories in Italy.
• MyRisk Plus Multigene germline blood test evaluating 48 genes linked to 11 hereditary cancer sites, helping determine a patient's hereditary cancer risk. Results are classified as Positive, Elevated, Negative, or Variant of Uncertain Significance (VUS). Performed at Myriad Genetics laboratories in the USA. Supports risk reduction through increased surveillance, chemoprevention, prophylactic surgery, and risk counseling. For oncologists, genetic counselors, and clinical geneticists in Italy.
• BiomeOne First-in-class CE-IVD fecal sample test predicting response to cancer immunotherapy (Immune Checkpoint Inhibitors: CTLA-4, anti-PD-1, anti-PD-L1) based on intestinal microbiota analysis. Delivers three output parameters: Clinical Response (CE-IVD, for identifying responders/non-responders), Tolerability (RUO, for predicting immune-related adverse events), and Diversity/Bacterial Richness/Enterotype (research use). Achieves over 80% prediction sensitivity, outperforming PD-L1 expression assays at approximately 65% sensitivity by over 20 percentage points. Validated on over 10,000 cancer patients. For medical oncologists treating NSCLC, RCC, and melanoma patients in Italy.

Quantifiable outcome

• >80% sensitivity for immunotherapy response prediction with BiomeOne vs ~65% for PD-L1 testing
• +5 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core.

• Eurobio ScientificcoreStrategic or Co-development Partner · 1 March 2025Eurobio Scientific acquired Quimark in March 2025. Effective October 7, 2025, Quimark Srl merged by incorporation with DID S.p.A., a company integrated into the Eurobio Scientific group. This merger strengthens Quimark's strategic positioning in the diagnostic-oncology sector through synergies with DID's existing activities and the Eurobio group's expertise. The group's proprietary products now represent 35% of revenue, with 42% of sales generated internationally.
• Canhelp GenomicscoreTechnology or Integration · 14 January 2025Quimark and Canhelp Genomics announced a precision diagnostics agreement in oncology for Italy. Quimark serves as the exclusive or primary Italian distributor for Canhelp Genomics products including Canhelp-Origin (tumor origin identification test) and Canhelp-UCa (bladder cancer urine test). Canhelp Genomics, based in China, provides the CE-IVD certified diagnostic kits while Quimark handles Italian market distribution, marketing, and customer support.
• Biome-DxcoreTechnology or IntegrationBiome-Dx is an Austrian company that manufactures and performs the BiomeOne test (world's first CE-IVD fecal microbiota test for predicting cancer immunotherapy response). Quimark distributes BiomeOne in Italy while Biome-Dx performs testing in its Austrian laboratories. The test is validated with 80 advanced cancer patients and data from >10,000 cancer patients across Europe and the US.
• Myriad GeneticscoreTechnology or IntegrationMyriad Genetics (USA) is the developer and laboratory provider for MyChoice CDx Plus (HRD testing for ovarian cancer) and MyRisk Plus (hereditary cancer germline testing). Quimark acts as the Italian channel partner, facilitating sample logistics from Italian patients to Myriad Genetics USA laboratories, with results reported back to Italian physicians via Myriad's secure computing platform.
• Divitum (Biovica)coreTechnology or IntegrationDivitum (developed by Biovica, Sweden) produces the DiviTum TKa test, a CE-IVD certified quantitative test measuring thymidine kinase 1 (TK1) activity for metastatic breast cancer proliferation monitoring. Quimark distributes DiviTum TKa in Italy. The test is based on multi-step endpoint ELISA technology.
• Myriad Genetics (EndoPredict)coreTechnology or IntegrationMyriad Genetics (USA) is the developer of EndoPredict (second-generation genomic breast cancer test). Quimark distributes EndoPredict in Italy as a CE-IVD kit (QS UNO 6 tests, QS DUO 12 tests) for use in molecular laboratories. The test quantifies 12 genes via RT-QPCR from FFPE breast tumor samples and has Level of Evidence 1A per ESMO guidelines.
• Myriad Genetics (Prolaris)coreTechnology or IntegrationMyriad Genetics (USA) developed Prolaris, a prognostic genomic prostate cancer test using cell cycle progression (CCP) score. Quimark distributes Prolaris in Italy. The test combines gene expression data with PSA and Gleason score. It is recommended by NCCN and ASCO guidelines, and trusted by >5 million patients globally.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Bio-Techne: Global life sciences tools and diagnostics company including ExoDx prostate cancer test and other oncology diagnostics. Comparable in molecular oncology diagnostics category and competes in some indications (prostate), though much larger and US-anchored.
• Hologic: US-headquartered diagnostics company with women's health and oncology molecular diagnostics portfolio. Comparable in oncology companion diagnostic category, though distribution model and geography differ from Quimark's Italian specialty distribution focus.
• Qiagen: Global molecular diagnostics leader with broad oncology test portfolio (including HRD and companion diagnostics). Comparable in product category overlap (CE-IVD molecular oncology kits), but operates globally with proprietary IP and direct sales rather than as an Italian distributor.
• Exact Sciences: US oncology diagnostics leader with Cologuard and Oncotype DX (acquired from Genomic Health) competing directly with EndoPredict/Prolaris. Comparable in oncology genomic testing category, though at materially larger scale and with proprietary IP.
• Roche Diagnostics: Global diagnostics division of Roche offering oncology IVD products and companion diagnostics including HRD testing. Comparable in product overlap (oncology molecular diagnostics) and competes with Quimark-distributed tests, but at vastly larger scale with direct manufacturer economics.

Regional players

• Menarini Diagnostics: Italian diagnostics subsidiary of Menarini Group with IVD products and laboratory services. Comparable as an Italian diagnostics operator in overlapping customer channels, though broader in therapeutic areas and self-manufactured.
• Euroimmun: European diagnostics company (owned by Revvity/PerkinElmer) with broad autoimmune and specialty diagnostics portfolio. Comparable as a European CE-IVD diagnostics operator with similar hospital/lab customer base, though broader therapeutic focus and self-manufactured.
• DiaSorin: Italian-headquartered global diagnostics company with broad IVD portfolio including oncology and specialty testing. Comparable as an Italy-based diagnostics operator, but operates at much larger scale with proprietary manufacturing rather than pure distribution.

Direct peers

• Diatech Pharmacogenetics: Italian molecular diagnostics distributor specializing in pharmacogenetics and oncology kits to Italian hospitals and labs. Directly comparable to Quimark in geography, customer base, and CE-IVD distribution model, though narrower in therapeutic focus.
• Sentinel Diagnostics: Italian IVD distributor and manufacturer serving clinical laboratories and hospitals with diagnostic kits. Comparable as a CE-IVD distribution-focused business in Italy, though broader in clinical chemistry rather than oncology-focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/74997266/admin/feed/posts

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quimark